
Stéphane Supiot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8183551/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 1884-1890.	1.6	521
2	Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncology, The, 2016, 17, 747-756.	10.7	317
3	Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1341-1352.	10.7	185
4	Cancer radioimmunotherapy with alpha-emitting nuclides. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 601-614.	6.4	148
5	Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncology, The, 2019, 20, 1740-1749.	10.7	147
6	Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Molecular Cancer Therapeutics, 2009, 8, 203-213.	4.1	95
7	Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1420-1429.	0.8	93
8	A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity. PLoS ONE, 2011, 6, e25220.	2.5	77
9	Interstitial brachytherapy of periorificial skin carcinomas of the face: A retrospective study of 97 cases. International Journal of Radiation Oncology Biology Physics, 2005, 63, 753-757.	0.8	73
10	Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Molecular Cancer Therapeutics, 2008, 7, 993-999.	4.1	66
11	Comparison of Automated Atlas-Based Segmentation Software for Postoperative Prostate Cancer Radiotherapy. Frontiers in Oncology, 2016, 6, 178.	2.8	63
12	Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer, 2002, 94, 1202-1209.	4.1	60
13	The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy. British Journal of Radiology, 2018, 91, 20170762.	2.2	57
14	Mechanisms of Cell Sensitization to α Radioimmunotherapy by Doxorubicin or Paclitaxel in Multiple Myeloma Cell Lines. Clinical Cancer Research, 2005, 11, 7047s-7052s.	7.0	52
15	Improved Functionality of the Vasculature during Conventionally Fractionated Radiation Therapy of Prostate Cancer. PLoS ONE, 2013, 8, e84076.	2.5	52
16	REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. Annals of Oncology, 2014, 25, 2351-2356.	1.2	51
17	Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions. Radiotherapy and Oncology, 2013, 106, 138-146.	0.6	50
18	Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumor Biology, 2012, 33, 679-688.	1.8	48

#	Article	IF	CITATIONS
19	OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer. European Urology, 2021, 80, 405-414.	1.9	48
20	Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how?. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2014, 18, 524-534.	1.4	47
21	OLICOPELVIS – GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer. BMC Cancer, 2015, 15, 646.	2.6	44
22	Videotaped simulated interviews to improve medical students' skills in disclosing a diagnosis of cancer. Psycho-Oncology, 2010, 19, 975-981.	2.3	43
23	Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review. Radiation Oncology, 2012, 7, 126.	2.7	42
24	Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nature Reviews Urology, 2015, 12, 193-204.	3.8	41
25	Cost of prostate image-guided radiation therapy: Results of a randomized trial. Radiotherapy and Oncology, 2013, 106, 50-58.	0.6	39
26	Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging. BMC Cancer, 2019, 19, 167.	2.6	39
27	LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1. Annals of Oncology, 2021, 32, S1299.	1.2	39
28	Voxel-Based Analysis for Identification of Urethrovesical Subregions Predicting Urinary Toxicity After Prostate Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 343-354.	0.8	37
29	PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status. Radiotherapy and Oncology, 2008, 86, 407-411.	0.6	36
30	No Impairment of Quality of Life 18 Months After High-Dose Intensity-Modulated Radiotherapy for Localized Prostate Cancer: A Prospective Study. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1053-1059.	0.8	36
31	Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07). International Journal of Radiation Oncology Biology Physics, 2019, 103, 1061-1067.	0.8	36
32	Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1243-1253.	0.8	35
33	Pharmacotherapeutic Management of Locally Advanced Prostate Cancer. Drugs, 2011, 71, 1019-1041.	10.9	34
34	Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU). Cancer Treatment Reviews, 2015, 41, 814-820.	7.7	34
35	Radiotherapy-induced overexpression of exosomal miRNA-378a-3p in cancer cells limits natural killer cells cytotoxicity. Epigenomics, 2020, 12, 397-408.	2.1	34
36	Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer. Colorectal Disease, 2006, 8, 430-435.	1.4	33

#	Article	IF	CITATIONS
37	Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: A feasibility study. World Journal of Gastroenterology, 2013, 19, 3249.	3.3	31
38	Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Molecular Cancer Therapeutics, 2002, 1, 267-74.	4.1	31
39	A phase I trial of pre-operative radiotherapy for prostate cancer: Clinical and translational studies. Radiotherapy and Oncology, 2008, 88, 53-60.	0.6	30
40	Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treatment Reviews, 2011, 37, 476-86.	7.7	29
41	Prognostic and predictive values of diffusion and perfusion MRI in paediatric intracranial ependymomas in a large national study. British Journal of Radiology, 2016, 89, 20160537.	2.2	29
42	Pediatric Localized Intracranial Ependymomas: A Multicenter Analysis of the Société Française de lutte contre les Cancers de l'Enfant (SFCE) from 2000 to 2013. International Journal of Radiation Oncology Biology Physics, 2018, 102, 166-173.	0.8	29
43	Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nature Reviews Clinical Oncology, 2011, 8, 107-113.	27.6	28
44	microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation. Molecular Cancer, 2020, 19, 63.	19.2	28
45	Using Simulated Interviews to Teach Junior Medical Students to Disclose the Diagnosis of Cancer. Journal of Cancer Education, 2008, 23, 102-107.	1.3	27
46	Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma. Radiotherapy and Oncology, 2017, 122, 362-367.	0.6	27
47	Re-irradiation of locally recurrent pediatric intracranial ependymoma: Experience of the French society of children's cancer. Radiotherapy and Oncology, 2019, 132, 1-7.	0.6	27
48	Influence of Radiotherapy Fractionation Schedule on the Tumor Vascular Microenvironment in Prostate and Lung Cancer Models. Cancers, 2020, 12, 121.	3.7	27
49	Optimizing radiotherapy protocols using computer automata to model tumour cell death as a function of oxygen diffusion processes. Scientific Reports, 2017, 7, 2280.	3.3	25
50	Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients. PLoS ONE, 2018, 13, e0194173.	2.5	24
51	A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer Journal of Clinical Oncology, 2016, 34, 5003-5003.	1.6	24
52	Reoxygenation during radiotherapy in intermediate-risk prostate cancer. Radiotherapy and Oncology, 2019, 133, 16-19.	0.6	23
53	Ameloblastic Fibrosarcoma of the Mandible. Journal of Pediatric Hematology/Oncology, 2012, 34, e72-e76.	0.6	22
54	Tumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacy. Cancer Letters, 2019, 457, 1-9.	7.2	21

#	Article	IF	CITATIONS
55	Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Frontiers in Oncology, 2016, 6, 24.	2.8	20
56	Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA). BMC Medical Informatics and Decision Making, 2019, 19, 2.	3.0	20
57	Binding Activities and Antitumor Properties of a New Mouse/Human Chimeric Antibody Specific for GD2 Ganglioside Antigen. Clinical Cancer Research, 2007, 13, 5613s-5620s.	7.0	19
58	Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder. Radiotherapy and Oncology, 2021, 161, 95-114.	0.6	19
59	Underestimation of dose delivery in preclinical irradiation due to scattering conditions. Physica Medica, 2014, 30, 63-68.	0.7	18
60	Can We Spare the Pancreas and Other Abdominal Organs at Risk? A Comparison of Conformal Radiotherapy, Helical Tomotherapy and Proton Beam Therapy in Pediatric Irradiation. PLoS ONE, 2016, 11, e0164643.	2.5	18
61	High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study. International Journal of Radiation Oncology Biology Physics, 2016, 96, 840-847.	0.8	18
62	Towards homogenization of total body irradiation practices in pediatric patients across SIOPE affiliated centers. A survey by the SIOPE radiation oncology working group. Radiotherapy and Oncology, 2021, 155, 113-119.	0.6	18
63	Technical note: Proton beam dosimetry at ultraâ€high dose rates (FLASH): Evaluation of GAFchromicâ"¢ (EBT3, EBTâ€XD) and OrthoChromic (OCâ€1) film performances. Medical Physics, 2022, 49, 2732-2745.	3.0	18
64	Management of non-metastatic castrate-resistant prostate cancer: A systematic review. Cancer Treatment Reviews, 2018, 70, 223-231.	7.7	17
65	Advances in nasopharyngeal carcinoma <i>—"West meets Eastâ€</i> . British Journal of Radiology, 2019, 92, 20199004.	2.2	17
66	Local dose analysis to predict acute and late urinary toxicities after prostate cancer radiotherapy: Assessment of cohort and method effects. Radiotherapy and Oncology, 2020, 147, 40-49.	0.6	17
67	Prospective evaluation of quality of life 54Âmonths after high-dose intensity-modulated radiotherapy for localized prostate cancer. Radiation Oncology, 2013, 8, 53.	2.7	16
68	Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study. Oncotarget, 2018, 9, 10005-10015.	1.8	16
69	Gemcitabine radiosensitizes multiple myeloma cells to low let, but not high let, irradiation. Radiotherapy and Oncology, 2007, 83, 97-101.	0.6	15
70	Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma. Radiotherapy and Oncology, 2018, 127, 103-107.	0.6	15
71	Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1189-1195.	0.8	15
72	Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18F-FDG in a Patient With Prostate Cancer. Clinical Nuclear Medicine, 2015, 40, 670-671.	1.3	14

#	Article	IF	CITATIONS
73	Monte Carlo evaluation of the effect of inhomogeneities on dose calculation for low energy photons intra-operative radiation therapy in pelvic area. Physica Medica, 2015, 31, 956-962.	0.7	14
74	Delineation of the Prostate Bed: The "Invisible Target―Is Still an Issue?. Frontiers in Oncology, 2017, 7, 108.	2.8	14
75	Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 193-198.	1.4	14
76	Post-Prostatectomy Image-Guided Radiotherapy: The Invisible Target Concept. Frontiers in Oncology, 2017, 7, 34.	2.8	13
77	Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis. PLoS ONE, 2019, 14, e0210514.	2.5	13
78	Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP. Oncotarget, 2018, 9, 22147-22157.	1.8	13
79	Moderately hypofractionated prostate external-beam radiotherapy: an emerging standard. British Journal of Radiology, 2018, 91, 20170807.	2.2	12
80	Respiratory-gated bilateral pulmonary radiotherapy for Ewing's sarcoma and nephroblastoma in children and young adults: Dosimetric and clinical feasibility studies. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2017, 21, 124-129.	1.4	11
81	Hippocampal Sparing During Craniospinal Irradiation: What Did We Learn About the Incidence of Perihippocampus Metastases?. International Journal of Radiation Oncology Biology Physics, 2018, 100, 980-986.	0.8	10
82	Clinical and diagnosis characteristics of breast cancers in women with a history of radiotherapy in the first 30 years of life: A French multicentre cohort study. Radiotherapy and Oncology, 2017, 124, 200-203.	0.6	9
83	Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy. British Journal of Radiology, 2018, 91, 20170824.	2.2	9
84	A new tissue segmentation method to calculate 3D dose in small animal radiation therapy. Radiation Oncology, 2018, 13, 32.	2.7	9
85	A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients. Health and Quality of Life Outcomes, 2018, 16, 40.	2.4	8
86	Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases. Biomedicines, 2020, 8, 548.	3.2	8
87	Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial—NCT00423475 Journal of Clinical Oncology, 2015, 33, 5006-5006.	1.6	8
88	The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy Journal of Clinical Oncology, 2017, 35, 16-16.	1.6	8
89	Haute Couture or Ready-To-Wear? Tailored Pelvic Radiotherapy for Prostate Cancer Based on Individualized Sentinel Lymph Node Detection. Cancers, 2020, 12, 944.	3.7	7
90	Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer. Frontiers in Oncology, 2021, 11, 744679.	2.8	7

#	Article	IF	CITATIONS
91	Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 787347.	2.8	7
92	External radiotherapy for prostatic cancers. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 329-343.	1.4	7
93	Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?. Cancers, 2020, 12, 635.	3.7	6
94	A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam. Cancers, 2021, 13, 1889.	3.7	6
95	Stereotactic Re-Irradiation for Local Recurrence after Radical Prostatectomy and Radiation Therapy: A Retrospective Multicenter Study. Cancers, 2021, 13, 4339.	3.7	6
96	Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial – PROFIT. Radiotherapy and Oncology, 2022, 173, 306-312.	0.6	6
97	OC-0309: Role of age, grade and RT dose on outcome of 177 ependymoma - 13 years experience of Child's cancer French Society. Radiotherapy and Oncology, 2015, 115, S155.	0.6	5
98	Integrating Geriatric Assessment into Decision-Making after Prostatectomy: Adjuvant Radiotherapy, Salvage Radiotherapy, or None?. Frontiers in Oncology, 2015, 5, 227.	2.8	5
99	Radical radiotherapy for paediatric solid tumour metastases: An overview of current European protocols and outcomes of a SIOPE multicenter survey. European Journal of Cancer, 2021, 145, 121-131.	2.8	5
100	Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer. Lung Cancer, 2021, 157, 100-108.	2.0	5
101	Prostate cancer with oligometastatic relapse: Combining stereotactic ablative radiotherapy and durvalumab, a randomized phase II trial (POSTCARD - CETUG-P13) Journal of Clinical Oncology, 2019, 37, TPS5088-TPS5088.	1.6	5
102	Guide for paediatric radiotherapy procedures. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 356-367.	1.4	5
103	Randomized Phase 3 Trial of Dose Escalation (80 vs 70 Gy) in High-Risk Prostate Cancers Combined With Long-term Androgen Deprivation: GETUG-AFU 18 Trial, Acute and 1-Year Toxicities. International Journal of Radiation Oncology Biology Physics, 2015, 93, S44-S45.	0.8	4
104	Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475) Journal of Clinical Oncology, 2019, 37, 5001-5001.	1.6	4
105	Oligometastatic prostate cancer: is it worth targeting the tip of the iceberg?. Translational Cancer Research, 2019, 8, S171-S175.	1.0	4
106	Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: A case report and review of the literature. Clinical and Translational Radiation Oncology, 2022, 32, 24-28.	1.7	4
107	Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group. Critical Reviews in Oncology/Hematology, 2022, 173, 103661.	4.4	4
108	Preclinical Evaluation of Intraoperative Low-Energy Photon Radiotherapy Using Spherical Applicators in Locally Advanced Prostate Cancer. Frontiers in Oncology, 2015, 5, 204.	2.8	3

#	Article	IF	CITATIONS
109	Advances in radiotherapy special feature. British Journal of Radiology, 2015, 88, 20150412.	2.2	3
110	Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18FDG PET/CT in a Patient With Prostate Cancer. Clinical Nuclear Medicine, 2016, 41, 746-747.	1.3	3
111	Breast lymphoma occurring after an invasive ductal breast carcinoma developed in the same area: A case report and literature review. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 167-170.	1.4	3
112	Feasibility of Dose Escalation in Patients With Intracranial Pediatric Ependymoma. Frontiers in Oncology, 2019, 9, 531.	2.8	3
113	Daily versus weekly prostate cancer image-guided radiotherapy: A phase 3, multicenter, randomized trial Journal of Clinical Oncology, 2018, 36, 4-4.	1.6	3
114	Post-Operative Radiotherapy in Prostate Cancer: Is It Time for a Belt and Braces Approach?. Frontiers in Oncology, 2021, 11, 781040.	2.8	3
115	Radiotherapy of bone metastases. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 368-376.	1.4	3
116	Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 780507.	2.8	3
117	Conservative management of a perianal rhabdomyosarcoma in a 2-year old child by Papillon's technique. Radiation Oncology, 2015, 10, 108.	2.7	2
118	OC-0171 Hypofractionated SBRT in childhood cancer: preliminary results of a national prospective study. Radiotherapy and Oncology, 2019, 133, S83-S84.	0.6	2
119	Late Toxicity and Quality of Life from GETUG-AFU 22 Study: A Multicenter Randomized Phase II Trial Comparing Radiotherapy +/- 6 Months of Degarelix as a Salvage Treatment for Patients with Detectable PSA after Radical Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2019, 105, S134.	0.8	2
120	Comparison of Machine Learning Algorithms and Oversampling Techniques for Urinary Toxicity Prediction After Prostate Cancer Radiotherapy. , 2019, , .		2
121	Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa). Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2021, 25, 400-409.	1.4	2
122	Intensity-modulated radiation therapy for pediatric head and neck rhabdomyosarcoma: French preliminary results Journal of Clinical Oncology, 2010, 28, 9549-9549.	1.6	2
123	Oncologic Impact and Safety of Pre-Operative Radiotherapy in Localized Prostate and Bladder Cancer: A Comprehensive Review from the Cancerology Committee of the Association Française d'Urologie. Cancers, 2021, 13, 6070.	3.7	2
124	Ensemble Learning for Prediction of Toxicity in Prostate Cancer Radiotherapy: Comparison Between Stacking and Genetic Algorithm Weighted Voting. , 2020, , .		2
125	Sorafenib (BAY 43-9006) Protects Normal Murine Gut From Radiation Damage. International Journal of Radiation Oncology Biology Physics, 2007, 69, S125.	0.8	1
126	Whole Ventricular Irradiation for Pediatric Intracranial Germ Cell Tumors: A Dosimetric Study Comparing Conformal, IMRT and Helical IMRT Irradiation. International Journal of Radiation Oncology Biology Physics, 2008, 72, S677-S678.	0.8	1

#	Article	IF	CITATIONS
127	Health-related Quality of Life after 76 Gy Intensity Modulated Radiotherapy for Localized Prostate Cancer: A Prospective and Longitudinal Study. International Journal of Radiation Oncology Biology Physics, 2008, 72, S102.	0.8	1
128	Response to "Intraoperative Radiotherapy During Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical and Dosimetric Aspects―(Int J Radiat Oncol Biol PhysÂ2009; in press). International Journal of Radiation Oncology Biology Physics, 2010, 76, 1277.	0.8	1
129	Respiration-Gated Radiation Therapy for Bilateral Pulmonary Radiation in Pediatric Cancers: Benefits on the Liver. International Journal of Radiation Oncology Biology Physics, 2012, 84, S639.	0.8	1
130	Hyperfractionated Radiation Therapy Alone for Standard-Risk Medulloblastoma: Pooled Data From MSFOP 98 and MSFOP 2007 Prospective Studies. International Journal of Radiation Oncology Biology Physics, 2016, 96, S230.	0.8	1
131	Treatment of cutaneous and/or soft tissue manifestations of corticosteroids refractory chronic graft versus host disease (<scp>cGVHD</scp>) by a total nodal irradiation (TNI). Clinical Transplantation, 2017, 31, e12923.	1.6	1
132	Prostate Hypofractionated Radiation Therapy With a Rectal Spacer Comparing Moderate Hypofractionation (62 Gy at 3.1 Gy per Fraction) Versus Stereotactic Irradiation (37.5 Gy at 7.5 Gy per) Tj ETQqO	0 0 rgBT /	Oyerlock 10
133	Oncology Biology Physics, 2017, 99, E218-E219. Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910–7. European Urology, 2018, 73, e34-e35.	1.9	1
134	Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 892-897.	1.4	1
135	Combined abiraterone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP Journal of Clinical Oncology, 2017, 35, 45-45.	1.6	1
136	SAKK 08/15-promet: Multicenter, randomized phase II trial of salvage radiotherapy +/- metformin for patients with prostate cancer after prostatectomy Journal of Clinical Oncology, 2018, 36, TPS157-TPS157.	1.6	1
137	Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective Study. Frontiers in Oncology, 2021, 11, 781121.	2.8	1
138	Synergism between gemcitabine and low LET (gamma-rays), but not high-let alpha-particles on multiple myeloma cell lines. International Journal of Radiation Oncology Biology Physics, 2004, 60, S373-S373.	0.8	0
139	539 POSTER Nutlin-3 radiosensitizes prostate cancer cell lines independent of p53 status. European Journal of Cancer, Supplement, 2006, 4, 163-164.	2.2	0
140	2BA PRIMA-1met as a potential prostate cancer radiosensitizer under normoxia and hypoxia. European Journal of Cancer, Supplement, 2007, 5, 10.	2.2	0
141	355 POSTER Combination therapy with sorafenib and radiation demonstrated improved survival in normal murine gut. European Journal of Cancer, Supplement, 2007, 5, 72.	2.2	0
142	4102 Preliminary results of intensity modulated radiation therapy for pediatric head-and-neck rhabdomyosarcoma in France. European Journal of Cancer, Supplement, 2009, 7, 221.	2.2	0
143	Preliminary Results of Fluorocholine (18F) PET/CT (FCH PET/CT) for Guiding Salvage IG-IMRT in Patients with an Occult Recurrence from a Previously Treated Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, S335.	0.8	0
144	Radio-induced Breast Cancers Display Aggressive Pathological Characteristics: A Retrospective Study by The French Pediatric Oncology Society (SFCE). International Journal of Radiation Oncology Biology Physics, 2011, 81, S664.	0.8	0

#	Article	IF	CITATIONS
145	Intérêt des traceurs de l'hypoxie en radiothérapie. Medecine Nucleaire, 2011, 35, 621-624.	0.2	Ο
146	17 Combining radiotherapy and new drugs in locally advanced prostate cancer. Critical Reviews in Oncology/Hematology, 2011, 78, S15-S16.	4.4	0
147	Corrigendum to "Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions―[Radiother Oncol 106 (2013) 138–146]. Radiotherapy and Oncology, 2013, 107, 263.	0.6	0
148	Impact of Functional and/or Phenotypic PET Imaging on the Determination of Clinical Target Volumes of Vertebral Metastases Before Stereotactic Body Radiation Therapy Compared to MRI. International Journal of Radiation Oncology Biology Physics, 2015, 93, S82-S83.	0.8	0
149	High Dose Hypofractionated Stereotactic Body Radiation Therapy of Non Compressive Vertebral Bone Metastases in Combination With Zoledronic Acid: A Phase 1 Study. International Journal of Radiation Oncology Biology Physics, 2015, 93, E83.	0.8	Ο
150	OC-0345: Patterns of failure after radiotherapy in pediatric ependymoma: correlation with dose parameters. Radiotherapy and Oncology, 2016, 119, S158-S159.	0.6	0
151	Radiothérapie pratique des métastases osseusesÂ: indications et techniques. Revue Du Rhumatisme Monographies, 2017, 84, 155-159.	0.0	Ο
152	Patterns of Daily Practice of Hormone Therapy in Unfavorable and Favorable Intermediate-Risk Prostate Cancer: Results of the French PROACT Survey. International Journal of Radiation Oncology Biology Physics, 2017, 99, E213.	0.8	0
153	Comment l'imagerie nucléaire modifie-t-elle la prise en charge par radiothérapie des cancers de prostateÂ?. Medecine Nucleaire, 2017, 41, 335-340.	0.2	Ο
154	Editorial: Controversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer. Frontiers in Oncology, 2017, 7, 275.	2.8	0
155	OC-0376: Hypofractionated RT: fractionation schedule affects tumour vascular morphology and functionality. Radiotherapy and Oncology, 2018, 127, S192.	0.6	Ο
156	OC-0538: Daily versus weekly prostate cancer image-guided radiotherapy: A Phase 3 randomized trial. Radiotherapy and Oncology, 2018, 127, S287.	0.6	0
157	PV-0623: Toxicity and Quality of Life of Salvage Pelvic Irradiation of Prostatic Cancer Node Relapse. Radiotherapy and Oncology, 2018, 127, S330.	0.6	Ο
158	EP-1920: Can delivered dose explain local recurrence in patients with prostate radiotherapy?. Radiotherapy and Oncology, 2018, 127, S1043-S1044.	0.6	0
159	EP-1943: Is dose escalation in intracranial pediatric ependymoma feasible with advanced radiation techniques?. Radiotherapy and Oncology, 2018, 127, S1055-S1056.	0.6	Ο
160	EP-1998: In silico modelling of the impact of the fractionation for hypofractionated prostate treatments. Radiotherapy and Oncology, 2018, 127, S1086-S1087.	0.6	0
161	PO-0828: Analysis of the urethro-vesical region for urinary toxicity prediction after prostate radiotherapy. Radiotherapy and Oncology, 2018, 127, S432-S433.	0.6	Ο
162	OC-0615 Predicting urinary toxicity via 2D and 3D dose map analyses in prostate cancer radiotherapy. Radiotherapy and Oncology, 2019, 133, S326.	0.6	0

#	Article	IF	CITATIONS
163	PO-0853 Bladder and urethra subregions predicting urinary toxicity after prostate cancer radiotherapy. Radiotherapy and Oncology, 2019, 133, S449.	0.6	0
164	EP-1521 IMRT for prostate cancer with seminal vesicle involvement : A multicentric retrospective analysis. Radiotherapy and Oncology, 2019, 133, S822.	0.6	0
165	SP-0677 Oligometastatic Prostate SBRT: The How, What, Where and When. Radiotherapy and Oncology, 2019, 133, S355-S356.	0.6	0
166	Medulloblastoma Molecular Subgroup and Hyperfractionated Radiation Therapy Alone for Standard Risk Medulloblastoma : Results of the Pool Data of MSFOP 1998 and 2007 Studies. International Journal of Radiation Oncology Biology Physics, 2019, 105, S108.	0.8	0
167	Radiotherapy in the management of children with gliomatosis cerebri in France. International Journal of Radiation Oncology Biology Physics, 2019, 105, 907.	0.8	0
168	Report of a unique case of gemcitabine-induced radiation recall myelitis following spinal cord irradiation. BJR case Reports, 2020, 6, 20190118.	0.2	0
169	Late Gastrointestinal Tolerance After Prostate Radiotherapy: Is the Anal Canal the Culprit? A Narrative Critical Review. Frontiers in Oncology, 2021, 11, 666962.	2.8	0
170	Role of radiation therapy in patients with bone metastasis. , 2022, , 909-920.		0
171	Radiation therapy for primary bone tumors. , 2022, , 727-753.		0
172	Prospective determination of long-term toxicity and quality of life (QoL) of patients with prostate cancer after intensity-modulated radiotherapy (IMRT) Journal of Clinical Oncology, 2012, 30, 151-151.	1.6	0
173	OLIGOPELVIS – GETUG P07, a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer: Preplanned analysis of acute toxicity Journal of Clinical Oncology, 2016, 34, 173-173.	1.6	0
174	Abstract A28: Mutational landscape of TP53 in localized prostate cancer. , 2017, , .		0
175	HGG-40. EXCEPTIONAL SYNCHRONOUS OCCURENCE OF A BRAF V600E MUTANT GLIOBLASTOMA AND A H3.3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA: A CASE REPORT. Neuro-Oncology, 2020, 22, iii351-iii351.	1.2	0